NurExone Biologic Inc.: NurExone Issues Annual Shareholder Letter

Calgary, Alberta--(Newsfile Corp. - December 15, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) ("we", "our", the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided

Related Keywords

Germany ,Leipzig ,Sachsen ,Jerusalem ,Israel General ,Israel ,United States ,Canada ,United Kingdom ,America ,Canadian ,American ,Lior Shaltiel ,Lyora Aharonov ,Shulamit Levenberg ,Twitter ,Company Or Nurexone ,Dean Of The Biomedical Engineering Department ,Nurexone Biologic Inc ,Facebook ,Alberta Newsfile Corp ,Venture Exchange ,Regulation Services Provider ,Drug Administration ,Yissum Research Development Company ,Youtube ,Nanometrix Ltd ,Israel Institute Of Technology ,Tel Aviv University ,Hebrew University Of Jerusalem Ltd ,Our Research ,Exone Biologic ,Public Listing ,North America ,North American ,Pre Investigational New Drug ,Scientific Advisory Board ,Biomedical Engineering Department ,Biological Research ,Research Development Company ,Hebrew University ,Europe Conference ,Nurexone Biologic ,Israel Institute ,Executive Officer ,Nurexone ,Biologic ,Issues ,Nnual ,Shareholder ,Setter ,